RT Journal Article SR Electronic T1 Phenotypic distinctions of BLM- and RMI1-associated Bloom syndrome JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.11.02.21265560 DO 10.1101/2021.11.02.21265560 A1 Ipek Ilgin Gönenc A1 Nursel H. Elcioglu A1 Carolina Martinez Grijalva A1 Seda Aras A1 Nadine Großmann A1 Inka Praulich A1 Janine Altmüller A1 Silke Kaulfuß A1 Yun Li A1 Peter Nürnberg A1 Peter Burfeind A1 Gökhan Yigit A1 Bernd Wollnik YR 2021 UL http://medrxiv.org/content/early/2021/11/10/2021.11.02.21265560.abstract AB Bloom syndrome (BS) is an autosomal recessive disease with characteristic clinical features of primary microcephaly, growth deficiency, skin lesions, cancer predisposition, and immunodeficiency. Here, we report the clinical and molecular findings of eight patients from six families diagnosed with BS. We identified causative mutations in all families, three different homozygous mutations in BLM and one causative homozygous mutation in RMI1. The homozygous c.581_582delTT (p.Phe194*) and c.3164G>C (p.Cys1055Ser) mutations in BLM have already been reported in BS patients, while the c.572_573delGA (p.Arg191Lysfs*4) is novel. Interestingly, whole-exome sequencing revealed a homozygous loss-of-function mutation in RMI1 in two BS patients of a consanguineous Turkish family. All BS patients had primary microcephaly, intrauterine growth delay, and short stature, presenting the phenotypic hallmarks of BS. However, a narrow face, skin lesions, and upper airway infections were observed only in some of the patients. Overall, patients with homozygous BLM mutations had a more severe BS phenotype compared to patients carrying the homozygous RMI1 mutation, especially in terms of immunodeficiency and associated recurrent infections. Low-level immunoglobulins were observed in all BLM-mutated patients, emphasizing the immunodeficiency profile of the disease, which should be considered as an important phenotypic characteristic of BS, especially in the current Covid-19 pandemic era.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Research Group FOR 2800, Chromosome Instability: Cross-talk of DNA replication stress and mitotic dysfunction, SP5 and SPZ to B. Wollnik and Germany's Excellence Strategy, Cluster of Excellence; Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells (MBExC; EXC 2067/1-390729940) to B. Wollnik.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent of all participants or their legal representatives was obtained prior to participation in the study. This study was performed according to the Declaration of Helsinki protocol and approved by the local institutional review board (University Medical Center Goettingen, Germany) under approval number 3/2/16.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe whole-exome sequencing raw data are not publicly available due to privacy or ethical restrictions. Processed genetic data generated or analyzed within this study are available upon request.